Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 109 of 110 Updated Nov 17, 2026

BPC-157 + KPV

Gut healing blend · gut-repair stack

ANECDOTAL + ANIMAL STUDIES · CYTOPROTECTIVE PENTADECAPEPTIDE (BPC-157) + ALPHA-MSH-DERIVED TRIPEPTIDE (KPV) BLEND

Mechanism of action

BPC-157 promotes angiogenesis (VEGFR2), stabilises gut barrier function, and accelerates epithelial repair; KPV exerts NF-kB-suppressing anti-inflammatory activity at the colonic mucosa via melanocortin pathway intermediates. Layered: BPC-157 drives repair while KPV damps the inflammatory signal that delays it.

Researched effects

Gut mucosal repair; inflammatory bowel symptom support; intestinal-barrier restoration; combined healing + anti-inflammatory action commonly stacked for leaky-gut/IBD anecdotal protocols

Dosing reported in literature

250-500 mcg BPC-157 + 500-1000 mcg KPV SC daily near area of concern, or oral compounded form 1-2x daily. Cycle 4-6 weeks on / 2-4 weeks off

Known concerns

Both components are research compounds with limited human safety data; injection-site reactions; theoretical immune modulation; not FDA-approved for any indication

Continue reading